期刊
BMJ GLOBAL HEALTH
卷 7, 期 8, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/bmjgh-2022-009838
关键词
infections; diseases; disorders; injuries; systematic review; health policy
资金
- UK Foreign, Commonwealth and Development Office [215091/Z/18/Z]
- Bill & Melinda Gates Foundation [OPP1209135]
- Wellcome [215091/Z/18/Z]
- European Union's Horizon 2020 research and innovation programme [874667]
- MRC [MR/T001151/1]
This study evaluated the availability and quality of clinical management guidelines for monkeypox globally and found that the existing guidelines are limited in number, low in quality, lack detail, and have a narrow range of topics covered. Most guidelines focus on adults, with limited recommendations for children, pregnant women, and people living with HIV. Treatment guidance primarily focuses on antiviral medications, with limited recommendations for supportive care and complications. The study highlights the urgent need for research on the treatment and prevention of monkeypox, including different risk populations.
Background Monkeypox (MPX) is an important human Orthopoxvirus infection. There has been an increase in MPX cases and outbreaks in endemic and non-endemic regions in recent decades. We appraised the availability, scope, quality and inclusivity of clinical management guidelines for MPX globally. Methods For this systematic review, we searched six databases from inception until 14 October 2021, augmented by a grey literature search until 17 May 2022. MPX guidelines providing treatment and supportive care recommendations were included, with no exclusions for language. Two reviewers assessed the guidelines. Quality was assessed using the Appraisal of Guidelines for Research and Evaluation II tool. Results Of 2026 records screened, 14 guidelines were included. Overall, most guidelines were of low-quality with a median score of 2 out of 7 (range: 1-7), lacked detail and covered a narrow range of topics. Most guidelines focused on adults, five (36%) provided some advice for children, three (21%) for pregnant women and three (21%) for people living with HIV. Treatment guidance was mostly limited to advice on antivirals; seven guidelines advised cidofovir (four specified for severe MPX only); 29% (4/14) tecovirimat, and 7% (1/14) brincidofovir. Only one guideline provided recommendations on supportive care and treatment of complications. All guidelines recommended vaccination as post-exposure prophylaxis (PEP). Three guidelines advised on vaccinia immune globulin as PEP for severe cases in people with immunosuppression. Conclusion Our results highlight a lack of evidence-based clinical management guidelines for MPX globally. There is a clear and urgent need for research into treatment and prophylaxis including for different risk populations. The current outbreak provides an opportunity to accelerate this research through coordinated high-quality studies. New evidence should be incorporated into globally accessible guidelines, to benefit patient and epidemic outcomes. A 'living guideline' framework is recommended. PROSPERO registration number CRD42020167361.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据